Silencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats

Zhengchao Wang,1,2 Qing Zhu,1* Pin-Lan Li,1 Romesh Dhaduk,1 Fan Zhang,1 Todd W. Gehr,1 and Ningjun Li1

1Department of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia; 2Laboratory for Developmental Biology and Neurosciences, College of Life Sciences, Fujian Normal University, Fuzhou, People’s Republic of China; and 3Department of Medicine, Division of Nephrology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia

Submitted 18 December 2013; accepted in final form 4 March 2014

Wang Z, Zhu Q, Li PL, Dhaduk R, Zhang F, Gehr TW, Li N. Silencing of hypoxia-inducible factor-1α gene attenuates chronic ischemic renal injury in two-kidney, one-clip rats. Am J Physiol Renal Physiol 306: F1236–F1242, 2014. First published March 12, 2014; doi:10.1152/ajprenal.00673.2013.—Overactivation of hypoxia-inducible factor (HIF)-1α is implicated as a pathogenic factor in chronic kidney diseases (CKD). However, controversy exists regarding the roles of HIF-1α in CKD. Additionally, although hypoxia and HIF-1α activation are observed in various CKD and HIF-1α has been shown to stimulate fibrogenic factors, there is no direct evidence whether HIF-1α is an injurious or protective factor in chronic renal injury. The present study determined whether knocking down the HIF-1α gene can attenuate or exaggerate kidney damage using a chronic renal ischemic model. Chronic renal ischemia was induced by unilaterally clamping the left renal artery for 3 wk in Sprague-Dawley rats. HIF-1α short hairpin (sh) RNA or control vectors were transfected into the left kidneys. Experimental groups were sham control, clip control, and clip/shRNA. Enalapril was used to normalize blood pressure 1 wk after clamping the renal artery. HIF-1α protein levels were remarkably increased in clipped kidneys, and this increase was blocked by shRNA. Morphological examination showed that HIF-1α shRNA significantly attenuated injury in clipped kidneys: glomerular injury indices were 0.71 ± 0.04, 2.50 ± 0.12, and 1.34 ± 0.11, and the percentage of globally damaged glomeruli was 0.02, 34.3 ± 5.0, and 6.3 ± 1.6 in sham, clip, and clip+shRNA groups, respectively. The protein levels of collagen and α-smooth muscle actin also dramatically increased in clipped kidneys, but this effect was blocked by HIF-1α shRNA. In conclusion, long-term overactivation of HIF-1α is a pathogenic factor in chronic renal injury associated with ischemia/hypoxia.

REDUCED RENAL TISSUE OXYGEN levels have been demonstrated in a large variety of chronic kidney diseases (CKD) in both human patients and in experimental animal models. Hypoxia in CKD results from a combination of structural and functional changes (12, 36). As a result, hypoxia-inducible factor (HIF)-1α has been reported to be consistently upregulated in almost all types of CKD (7, 16, 17, 36–38). However, it is unclear whether upregulation of HIF-1α is beneficial or deleterious in progressive CKD. HIF-1α is a transcription factor and has been shown to stimulate collagen accumulation (7, 15, 43, 44) and promote the epithelial-to-mesenchymal transition (EMT) (11, 35), an important mechanism involved in the progression of CKD (3, 33, 57, 67). Therefore, although upregulation of HIF-1α is protective in acute kidney injury (9, 18, 37, 53), ample evidence indicates that long-term overactivation of HIF-1α may be a pathogenic factor in CKD (10, 16, 21, 24, 36, 45).

Previous studies have shown that genetic ablation of renal epithelial HIF-1α inhibits the development of renal tubulointerstitial fibrosis in unilateral ureteral obstruction rats (15) and that overexpression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis in 5⁄6 nephrectomy mice (23). We have also reported that silencing HIF-1α gene expression attenuates angiotensin II-induced profibrotic effects and transforming growth factor (TGF) β1-induced EMT in renal cells in vitro and in vivo (13, 62, 71). A more recent study has shown that increasing HIF-1α level exacerbates the kidney damage in a rat model of hypertension induced by a high-salt diet and nitric oxide withdrawal (5). Taken together, these studies suggest that overactivation of HIF-1α is an injurious factor in CKD.

However, there have been controversial reports regarding the role of HIF-1α in CKD. Induction of HIF-1α by CoCl2 ameliorates the renal injury in rats with nephritis (60) and hypertensive type 2 diabetes (46). In contrast to the deleterious effects of overexpressed HIF-1α in 5⁄6 nephrectomy mice (23), other reports have shown that upregulation of HIF-1α by pharmacological agents protects the kidneys using the same 5⁄6 nephrectomy model of CKD (6, 56, 59). Thus more detailed investigations are required regarding the role of the HIF-1α pathway in CKD under different situations.

Because of these disparate observations, it is imperative to clarify the role of HIF-1α in CKD. This clarification is critical for the application of HIF-1α activation or inhibition as a potential therapeutic strategy. The present study was to further elucidate whether ischemia-induced activation of HIF-1α is a beneficial or injurious factor in chronic kidney damage. We used a two-kidney, one-clip (2K1C) rat model treated with an angiotensin-converting enzyme (ACE) inhibitor so as to eliminate the possible effect of activation of the renin-angiotensin system in this model. By using this model, we attempted to minimize other impacts and evaluate the effect of increased HIF-1α on chronic renal injury in clipped kidneys. The present study determined whether silencing HIF-1α gene expression by short hairpin (sh) RNA attenuates or exaggerates renal injury in the clipped kidneys in 2K1C rats. To our knowledge, the present study provides the first direct evidence that chronic
MATERIALS AND METHODS

Animals. Experiments were performed using male Sprague-Dawley rats (250–350 g, Harlan, Madison, WI) with free access to food and water throughout the study. All animal procedures were approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University.

Plasmids expressing rat HIF-1α shRNA. Predesigned rat HIF-1α siRNA was purchased from Sigma-Aldrich. Sequences of HIF-1α siRNA were sense, GGA AAG AGA CUC AUA GAA A; and antisense, UUU CUA UGA CUC UCU UUC C. After confirmation of effective knockdown of HIF-1α genes by these siRNAs in cultured rat renal cells, the sequences were constructed into a pRNA-CMV3.2 vector (Genscript, Piscataway, NJ) to produce shRNA. The effective silencing of the renal HIF-1α gene by shRNA in vivo was verified in our previous studies (62, 71). Plasmids expressing luciferase were used in control animals.

Transfection of DNA into the kidney. DNA was transfected into the rat kidneys as we described previously (66, 71). In brief, rats were anesthetized with 2% isoflurane, and 50 µg of plasmids mixed with 8 µl of in vivo jetPEI (Polyplus Transfection, New York, NY) in 10% glucose (600 µl) were injected into the kidneys via the left renal artery when the renal artery and vein were temporarily blocked (<5 min). After injection, an ultrasound transducer (Sonitron 2000, Rich-Mar) was applied directly onto the kidney with an output of 1 MHz at 10% power for a total of 60 s with 30-s intervals, and then the renal artery and vein were unblocked to recover renal blood flow. This technique has been shown to effectively deliver DNA into the renal cells without toxicity to the kidney (26, 27, 41, 66, 71). The transfection reagent in vivo jetPEI, a polyethylenimine derivative, has been used to successfully deliver DNA into renal cells in vivo in previous studies, including ours (8, 29, 34, 63, 69, 70). In addition, a combination of ultrasound and different transfection reagents (19, 30, 40), including ours (8, 29, 34, 63, 69, 70). In this technique, DNA was delivered directly to the cell nucleus using ultrasound, which results in efficient gene delivery without toxicity to the kidney.

Human CD14+ monocytes as a model of monocyte/macrophages were transfected with the pRNA-CMV3.2 vector encoding shRNA targeting HIF-1α. Transfected cells were used for in vitro and in vivo experiments. In vitro, monocytes/macrophages were transfected in 6-well plates (4 × 10^6 cells/well) for 48 h. After transfection, cells were cultured in RPMI-1640 medium supplemented with 10% FBS. In vivo, the shRNA-expressing plasmids were injected into the rat kidney via the left renal artery and vein using an ultrasound transducer. The kidneys were harvested 24 h after transfection.

RESULTS

Changes in arterial pressure. MAP was significantly increased in 2K1C rats, suggesting the successful generation of a renal ischemic model (Fig. 1). Treatment with an ACE inhibitor, enalapril, normalized MAP in clipped rats (Fig. 1), which indicates the successful generation of the model. The MAP was significantly higher in clipped rats compared to sham-operated rats. The MAP was normalized by enalapril treatment.

Preparation of tissue homogenate and nuclear extracts and Western blot analyses for protein levels of HIF-1α, collagen I/III, and α-smooth muscle actin. Renal tissue homogenates and nuclear protein were prepared, and Western blot analyses were performed as we described previously (32). Primary antibodies used in the present study included anti-rat HIF-1α (monoclonal, 1:300 dilution, Novus Biologicals), collagen I/III (rabbit polyclonal, 1:300, Calbiochem), and α-smooth muscle actin (α-SMA; rabbit polyclonal, 1:1,000, Abcam). The intensities of the bands were determined using an imaging analysis program (ImageJ, free download from http://rsbweb.nih.gov/ij/).

Morphological and immunohistochemical analysis. The fixed kidneys were paraffin-embedded and cut into 4-µm sections. For morphological analysis, the tissue sections were stained with periodic acid-Schiff (PAS). Glomerular damage was morphologically evaluated by two independent examiners who were blinded to animal groups. The damage was semiquantitatively scored based on the degree of glomerular damage as described previously (39, 51). In brief, the percentage of glomeruli with tuft area involvement was scored as 0 = normal; 1 = 1–25% of glomerular area involved; 2 = 26–50%; 3 = 51–75%; and 4 = >75% of tuft area involved. The averaged scores from counted glomeruli were used as the glomerular damage index for each animal.

Immunostaining was performed as we described before (32) using antibodies against rat α-SMA (rabbit polyclonal, 1:200, Abcam). Collagen I/III was stained using picro sirius red, and the percentage of positive-stained area was calculated using a computer program (Image-Pro Plus) as described previously (61).

Statistics. Statistics were performed using SigmaStat. Data are presented as means ± SE. The significance of differences in mean values within and among three experimental groups was evaluated using ANOVA, and any significant differences revealed by this procedure were further investigated using appropriate post hoc tests as indicated in results. P < 0.05 was considered statistically significant.

Fig. 1. Changes in mean arterial blood pressure (MAP). Angiotensin-converting enzyme-1 (ACEI) indicates the start of enalapril treatment. *P < 0.001 vs. other 2 groups by 2-way repeated measures ANOVA (n = 7).
Effects of HIF-1α shRNA on histological changes in the glomeruli in clipped kidneys. Morphological analysis showed significant glomerular damage in clipped kidneys as indicated by glomerular mesangial expansion with hypercellularity, capillary collapse, and fibrous deposition in glomeruli (Fig. 3A). The glomerular damage index was substantially greater in clipped kidneys (Fig. 3A and B). Strikingly, the significantly larger number of globally damaged glomeruli in clipped kidneys was dramatically reduced by HIF-1α shRNA (Fig. 4). These results suggested that activation of HIF-1α mediates ischemia-induced glomerular injury.

**DISCUSSION**

The present study showed that chronic renal ischemia/hypoxia increased HIF-1α levels and that gene silencing of HIF-1α significantly attenuated the renal morphological changes and blocked the upregulation of α-SMA and collagen accumulation in clipped kidneys. These effects were independent of angiotensin II and hypertension. It is suggested that overactivation of
HIF-1α in the kidney is a crucial mediator in chronic renal injury associated with hypoxia.

Although hypoxia and upregulation of HIF-1α are observed in a variety of CKD models, there is no direct evidence whether HIF-1α is an injurious or protective factor in kidney damage under chronic hypoxic conditions. Different CKD models may exhibit complex mechanisms and signaling pathways as well as interactions among the signaling pathways. It may therefore be difficult to eliminate other factors and dissect the effects of HIF-1α in these CKD models. The model used in the present study has been shown to produce hypoxia in the kidneys (49, 50). By using this model, we attempted to minimize other possible influences on kidney damage in addition to ischemia-induced HIF-1α accumulation. It is well known that the 2K1C model activates the renin-angiotensin system and increases angiotensin II levels (1). Angiotensin II significantly affects renal function and has been shown to cause kidney damage (2, 38, 54). Normalization of MAP by enalapril indicated that the potential effect of angiotensin II on chronic renal injury was minimized in the present study. It allowed us to evaluate the effect of HIF-1α with minimal influence of other factors on the kidney damage in clipped kidneys, although we could not totally rule out the possible effects of other factors, if any. It should be noted that ACE inhibition has been shown not to improve the reduced oxygenation in the clipped kidney in the 2K1C model (49, 50), and therefore ACE inhibition would not affect HIF-1α levels beyond its action on the angiotensin II system in the present study.

The present study showed that chronic ischemia/hypoxia caused an increase in HIF-1α levels, which was accompanied by both glomerular and tubulointerstitial damage in clipped kidneys. Analyses of the glomerular damage index and the percentage of globally damaged glomeruli showed that chronic ischemia produced glomerular injury and that inhibition of HIF-1α expression substantially attenuated glomerular injury in clipped kidneys, demonstrating that activation of HIF-1α importantly participated in the glomerular injury under ischemic conditions. In addition, it has been shown that renal...
The beneficial effect of HIF-1α accumulation is a beneficial factor in CKD. It is interesting to note that all the studies using genetic approaches to locally manipulate HIF-1α levels within the kidneys demonstrate that HIF-1α is an injurious mediator and that almost all reports using pharmacological approaches to systemically increase HIF-1α levels show that HIF-1α is a protective factor. A more recent study demonstrated that globally genetic activation of HIF-1α may impact inflammation and fibrosis differentially. The beneficial effect of HIF-1α activation by pharmacological approaches may be produced by actions outside the kidneys. Therefore, local and global activation of HIF-1α may play different roles in the progression of CKD, which requires further investigation. Nevertheless, the present study provided strong evidence that long-term overactivation of HIF-1α within the kidney mediates renal damage.

In summary, the present study demonstrated that inhibition of HIF-1α overactivation in the kidneys attenuated renal injury under chronic ischemic/hypoxic conditions. It is suggested that overactivation of HIF-1α-mediated gene regulation in the kidney may constitute a pathogenic pathway mediating renal injury under various pathological conditions associated with ischemia and that normalization of overactivated HIF-1α in the kidneys may be a useful strategy in the treatment of chronic kidney damage associated with elevated levels of HIF-1α.

GRANTS
This work was supported by National Institutes of Health Grants HL-89563, HL-106042, and DK-54927.

DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS
REFERENCES


